AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...

The investment will fund a new drug manufacturing facility in Virginia, and expand research and development in at least 5 ...

AstraZeneca CFO Aradhana Sarin tells Yahoo Finance the company sees US innovation threatened by China, even as it commits $50 ...

With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...

While value has outperformed growth in Europe over the past five years, Europe now represents less than half of equity market ...

The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and ...

AstraZeneca has announced $50bn investment plans in the US by 2030 for drug manufacturing, and research and development (R&D) ...

President Donald Trump referenced the announcement the following day in Oval Office remarks, framing AstraZeneca’s overall ...

On a per-share basis, the Cambridge, Britain-based company said it had net income of 79 cents. Earnings, adjusted for non-recurring costs, came to $1.09 per share. The results met Wall Street ...

Merck is a strong and profitable pick meeting Benjamin Graham's criteria. Read more on why investors need to stay aware of ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

(Alliance News) - AstraZeneca raised its dividend as drug growth pushed earnings higher, Barclays launched a new buyback programme after profit jumped while Greggs saw profit fall despite higher sales ...